Amish infantile epilepsy syndrome

Amish infantile epilepsy syndrome, also known as PNKP-related infantile epileptic encephalopathy or Amish lethal microcephaly-like syndrome with epilepsy, is a rare autosomal recessive neurological disorder predominantly described in the Old Order Amish population due to a founder effect. It is caused by biallelic mutations in the PNKP gene (polynucleotide kinase 3'-phosphatase), which plays a critical role in DNA repair. The condition primarily affects the central nervous system, leading to severe seizures beginning in infancy, progressive microcephaly, and profound developmental delay. Affected infants typically appear normal at birth but develop intractable seizures within the first months of life. The seizures are often resistant to standard antiepileptic medications. Additional features include progressive cerebral atrophy visible on brain imaging, severe intellectual disability, and failure to achieve developmental milestones. Some patients may also exhibit peripheral neuropathy and liver dysfunction. The clinical course is generally severe, with significant neurological deterioration over time. There is currently no cure or disease-specific treatment for Amish infantile epilepsy syndrome. Management is primarily supportive and symptomatic, focusing on seizure control with antiepileptic drugs, nutritional support, and physical therapy. Despite aggressive treatment, seizures often remain refractory. Genetic counseling is important for affected families, particularly within the Amish community where carrier frequency for the founder mutation may be relatively high. Prognosis is generally poor, with many affected children experiencing severe disability and shortened lifespan.

Common questions about Amish infantile epilepsy syndrome